Objective -To assess the cost effectiveness ofadding universal hepatitis B vaccination in infancy or pre-adolescence to a policy of selective vaccination of at risk groups. Design -Costs of a selective policy and additional costs of universal vaccination policies were estimated from costs of vaccine delivery and published data on target populations. Additional years oflife gained were calculated for each policy by applying life tables to estimates of mortality attributable to hepatitis B. (J Epidemiol Community Health 1995;49:238-244) 
£2568, £2824, and £8564 respectively). Add Although infection with Hepatitis B virus can be asymptomatic, it is also associated with disease ranging from acute hepatitis (and rarely fulminant liver failure) to chronic liver disease and primary liver cancer. Hepatitis B vaccine has an efficiency >90%,' 2 no serious side effects, and has been available since the early 1980s.
Countries of low endemicity, including the United Kingdom where most transmission occurs in adulthood, have implemented selective vaccination policies aimed at adults in high risk categories combined with selective or universal antenatal testing and provision of vaccination to babies born to women who are hepatitis B carriers. High risk categories include close contacts of people with the virus, injecting drug users, those who frequently change sexual partners, and people occupationally or therapeutically exposed to blood.
Effective vaccine delivery with a selective policy is difficult. The World Health Organization has suggested that all countries should re-examine their hepatitis B control strategies.3 In the United States and Italy universal vaccination in infancy is now recommended,45 and there is support for a similar change in Canada. 6 The benefits of vaccination against hepatitis B are not easily perceived in countries of low endemicity. This is partly because of the low prevalence of carriage and hence risk of infection and partly because of the long lag between infection and the uncertain probability of chronic liver disease or cancer. Economic considerations probably also play a part in the continuation of a selective policy in the UK and other low prevalence countries.
We therefore examined the relative cost effectiveness of the current selective policy versus universal vaccination in infancy or preadolescence. It is likely that selective vaccination of adults will continue for some time so the incremental cost effectiveness of adding either of the two universal vaccination policies to selective vaccination was also estimated. Overhead costs and social costs incurred in providing and attending for vaccination in infancy and pre-adolescence were not included as current facilities and patient visits, or school attendance for a pre-adolescent policy, would be used. For the selective policy, although the first dose would be given opportunistically, attendance for second and third visits will have indirect costs. This was estimated as equivalent to an hour of time per adult patient for the second and third doses, at a cost of £12-50 per hour. The opportunity costs for services targeting drug users were also included as a new clinical service would be needed in addition to the more usual role of providing counselling or detoxification. Overheads for equipment such as refrigerators, waste disposal, and storage space for drug clinics and cold chain were estimated as an extra cost of £1 per dose (on the assumption that £500 per clinic would be needed for equipment lasting five years, with an average of two to three doses given each week.)
Method
Cost savings to the health service in reducing the incidence of acute and chronic liver disease and indirect costs (form work related loss of income, or the monetary value of lives lost) were not included. Some cost-benefit analyses in the USA have included these savings but not the extra costs of health services and social care of those who remain alive. Health sector savings would be offset both by the cost of services for people who live longer, with the replacement of hepatitis B by other terminal diseases. The net effect is not easily calculable and so was not included. This is a problem in many cost-effectiveness studies, and requires further research.
DESCRIPTION OF THE VARIOUS VACCINATION POLICIES
It was assumed that the time schedule for the three doses of hepatitis B vaccine in infancy was integrated with the other infant vaccinations using a combined preparation with Haemophilus influenzae B vaccine or the with diphtheria/polio/tetanus vaccine. Thus, only two intramuscular injections for the full infant vaccination schedule would be given at each visit. Extra nursing time was needed to provide the counselling and clerical work specifically for the hepatitis B vaccine. Vaccine uptake was assumed to be 92%, as is presently achieved for routine infant vaccinations. 12 It was assumed that one dose in pre-adolescence would be administered at the same time as tuberculin skin testing before BCG administration and that the remaining two doses would be given alone, since the current rubella vaccination programme will end when the cohort of children in the UK now being given MMR at age 18 months reaches 13 years of age. The time for administering each dose was estimated at 10 minutes for doses given alone and five minutes for the dose given with the tuberculin skin testing. Vaccine uptake was assume to be 80%, as is achieved for rubella vaccination.l2 The cost of the selective policy was based on vaccination of all newly-presenting adults in risk categories recommended for vaccination '3 and attending health services where vaccination would be available. The size of each population was estimated from sources given in table 2. t From estimating 64%42 of episodes of infection noted at genito-urinary (GUM) clinics49 were first episodes, 10% of men were gay*) and assuming, as for gay men, half were attending for the first time.
* Calculated from a 10% turnover50 of nursing, midwifery, medical, dental, and professional and technical staff as well as staff working in homes for those with mental handicap. § Data from 1986 indicate that a third or more of prisoners discharged re-enter custody within 2 years.5' ¶ Estimated using a life expectancy of 50 years."2 ** Estimated assuming turnover equal to number of discharges and deaths of those staying more than 1 year.
tt Based on present life expectancy"0 of a birth cohort in 1991 reaching age 11 years. The results were, however, sensitive to discounting. Discounting health gain at 6% per year, reduced considerably the number ofyears of life gained by each policy, more so for an infant compared with a pre-adolescent policy. Pre-adolescent vaccination became the most cost effective followed by infant vaccination, with the selective policy being the least cost effective. Universal pre-adolescent vaccination added to a selective policy also became more cost effective than adding universal infant vaccination (table 6) .
The cost effectiveness of universal vaccination compared with a continuing selective policy was only sensitive to the burden of disease in risk groups and health care utilisation rates in these groups in the analysis using discounted years (table 4) . The cost per discounted year of life saved in a selective policy became equivalent to the cost of universal infant vaccination in two plausible scenarios. The first was if 70% rather than 60% of all diseases occurred in those at risk and if 65% rather than 50% of all those at risk who go on to get disease had attended health care services. The second scenario was if the size of the population was in fact only three quarters of that estimated.
The relative cost effectiveness of pre-adolescent compared with infant vaccination in terms ofdiscounted years oflife saved remained robust to the uncertainty of the estimates used.
Discussion
If future health gained is as important as present gain32 the most cost effective policy in a low prevalence country like the UK is universal vaccination in infancy rather than in pre-adolescence. Universal infant vaccination would cost £2198 per year of life gained (converted to 1990 prices) equivalent to rental trans- plantation which costs £2000 and breast cancer screening which costs £3000 per quality adjusted year of life gained in 1990.32 Universal vaccination also compares favourably with the current selective policy for hepatitis B vaccination which would cost £7331 per year of life saved at 1990 prices. Implementing a universal infant or pre-adolescent policy in addition to a selective policy would be equivalent in 1990 to £1316 and £1419 per additional year of life gained respectively. Comparing a simple outcome measure ofthe cost per year of life saved with other health care interventions underestimates the effect of vaccination against hepatitis B. Infection as an adult results in acute symptomatic hepatitis in a third of cases, which may last for several weeks, and can carry stigma, as do other infections transmitted by sex or drugs, but is rarely fatal. Chronic infection with the virus can cause ill health from chronic persistent hepatitis and chronic active hepatitis which can last many years. These disease states can progress to cirrhosis with death being proceeded by decompensation into episodic bleeding from oesophageal varices, liver failure, or peritonitis. Sufficient data are not yet available, however, to produce more than a tentative measure of these various states in the form of quality adjusted life years or in the net cost of health care and social services if patients did not die from the long term effects of hepatitis B infections. Reflecting some of the morbidity prevented in quality adjusted life years in this analysis did not affect the ranking of the efficiency of the various vaccination strategies for hepatitis B, and made vaccination only slightly more cost effective than other health care interventions. Given that the main benefits of preventing hepatitis B infection lies in extending life and not quality of life, estimates of benefits are not greatly improved by adjustment for quality of life.
We have used a retrospective approach, measuring the cost in one year of each of the policies and the future years of life gained in those vaccinated. Some of the extra benefits of vaccination are reflected in the quality of life years estimates but it is also reassuring that transmission from those vaccinated is less likely. The indirect benefits arising from this, however, will not accrue for a long time because of the large pool of infection carriers in the community.
An estimated prevalence of hepatitis B carriage in the general population of 0 5% was considered appropriate as it yielded estimates of liver disease attributable to hepatitis B that were consistent with the proportion of cases due to hepatitis B in hospital case series data of white patients.2"-2" If the prevalence of hepatitis B carriage were lower this analysis showed that a continuing selective policy would still be relatively more expensive than the universal policies. The ranking of the cost effectiveness of hepatitis B vaccination compared with other health care interventions would, however, be affected.
The ranking of the various vaccination policies was extremely sensitive to the discounting of health gains in the future. Pre-adolescent vaccination became much more cost effective than infant vaccination. This was to be expected because of the postponement of benefits. In the UK most infections do not occur until adult life. The shorter gap between vaccination and health gain in a pre-adolescent policy means that benefits are discounted less heavily. This analysis highlights the importance ofthe current debate over the use ofdiscounting in economic analyses."236 As discussed by Parsonage and Neuberger, discounting "reflects the fact that individuals generally prefer income today to income tomorrow and so expect to be compensated for any deferral, for instance by receiving a positive real rate of interest on their savings" and allows appraisal of several different health policies by "putting differently dated costs and benefits on a common footing".'2 A few researchers, however, have emphasized "the question of the tradability of health both with wealth and future health".'6 For instance it is impossible to trade a year of life now for a year in the future. The second argument against discounting ofhealth benefits is the suggestion that in fact "the private discount rate for health is zero or even negative".6 Policy makers must take a view on this debate. This analysis shows empirically the importance of showing undiscounted as well as discounted health gains, as whether or not discounting is used affects the judgement of the efficiency of vaccination in pre-adolescence or infancy.
Selective vaccination is good medical practice but seemed the least effective use of resources. The costs of a selective strategy are also likely to have been underestimated because several factors were not taken into account. These include: the possible lower vaccine efficacy in adult risk groups compared with children,'7 the cost of vaccinating contacts of cases and carriers, and the organisation and education required to supply and deliver the vaccine. A selective policy is difficult to implement properly because of the variety of risk groups. Effective delivery in the UK has also not yet been demonstrated. '4 Universal antenatal testing instead of selective antenatal testing combined with appropriate vaccination of infants born to carrier mothers has recently been suggested for consideration." The potential maximum benefit of universal antenatal testing and vaccination of infants born to carrier mothers had only a small effect on the attractiveness of universal vaccination against hepatitis B compared with other preventive interventions. The present day costs of universal antenatal testing would be more than three million pounds per year. With a universal vaccination policy, women would no longer need to be tested when the vaccinated cohorts reach reproductive age. These savings would not start to be seen for one or more decades and so would be heavily discounted. Even so the biases from not including the savings in our analysis would favour a selective policy. An infant vaccination programme might also reduce the need to recall about 2000 newborns to carrier mothers per year for their second and third doses as they could be provided within the routine infant vaccination schedule. Delaying the second dose from one to two months to fit in with routine vaccination, in accordance with guidelines in the USA,4 will not be a problem as hepatitis B is highly immunogenic in infancy and the dose interval has little effect on this. '8 Another possible source of bias in this analysis is that costs were based on estimates of the new population for each policy while the years oflife gained were calculated from current incidence. This numerator/demoninator bias is most likely to affect the estimated cost effectiveness of a selective policy. The following factors, however, became important only if discounted years of life were used: the proportion of all deaths attributable to being in an at risk group, health care utilisation rates, and, to a lesser extent, the size of the population at risk that would be vaccinated.
The current incidence ofchronic liver disease used to calculate years of life gained reflects risk of infection 10-45 years earlier. The effect ofincluding deaths in migrants (who would not have been protected by vaccination strategies in the UK) was small since only 5% of deaths from primary liver cancer were in persons born abroad.39 Both these influences on the years of life gained would have affected all hepatitis B vaccination policies equally so that the relative ranking of the policies would not be altered.
This economic analysis is based on the imperfect data currently available in low prevalence countries and highlights the further information that would help other countries including the UK in determining the most cost effective hepatitis B vaccine policy. This includes data on the burden of morbidity and mortality occurring in individuals in high risk groups, the likely utilisation rates of health care services by those in high risk groups, the acceptability of vaccination by different age groups, and operational research to assess the feasibility of introducing a pre-adolescent policy.
There are limitations to economic analyses. Costs may change. For example if, as has been suggested in countries like Canada, hepatitis B vaccination is provided in pre-adolescence with the simultaneous delivery of other programmes to promote reproductive health, the costs of a pre-adolescent hepatitis B vaccination programme will be reduced. The political and professional will, as well as the education re-quired to change an existing vaccination programme also need to be considered. Finally factors other than optimal use of societal resources may be important. This analysis does not take into account the desirability of reaching groups already socially or economically disadvantaged, the prevention of rare occurrences of child to child transmission or removing the risk of those in contact with infectious individuals.
The current preference for a selective policy in low prevalence countries may be based on perceived economic efficiency. We have attempted and analysis of the cost effectiveness of the various vaccine policies for hepatitis B using data currently available in the UK. The analysis indicates that selective vaccination may not be the most cost effective strategy in preventing mortality, let alone morbidity, from hepatitis B and that addition of universal vaccination against hepatitis B to a selective policy may be no more expensive than some other established public health interventions.
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